# PROCESS VALIDATION PROTOCOL
## Fampridin (4-Aminopyridine) Manufacturing Process

**Prospective Validation – Three Commercial-Scale Batches**

---

**Document Number:** PVP-FAM-001  
**Version:** 1.0  
**Effective Date:** 04. Dezember 2025  
**Protocol Status:** Draft for Approval  

---

**Product:** Fampridin (4-Aminopyridine)  
**CAS Number:** 504-24-5  
**Batch Size:** 100 kg (per batch)  
**Number of Validation Batches:** 3  

---

**Prepared by:** Validation Manager  
**Reviewed by:** QA Manager, Production Manager, QC Manager  
**Approved by:** Management Representative  

---

## DOCUMENT CONTROL

| Version | Date | Author | Description of Changes |
|---------|------|--------|------------------------|
| 1.0 | 04.12.2025 | Validation Department | Initial Protocol |

---

## TABLE OF CONTENTS

1. Objective
2. Scope
3. Responsibilities
4. Product Description
5. Manufacturing Process Description
6. Critical Quality Attributes (CQAs)
7. Critical Process Parameters (CPPs)
8. In-Process Controls (IPCs)
9. Equipment and Utilities
10. Sampling Plan
11. Analytical Testing Plan
12. Acceptance Criteria
13. Validation Batch Execution
14. Data Recording and Documentation
15. Statistical Evaluation
16. Deviations
17. Conclusion and Approval
18. Appendices
19. References

---

## 1. OBJECTIVE

The objective of this Process Validation Protocol is to demonstrate that the manufacturing process for **Fampridin (4-Aminopyridine)** consistently produces Active Pharmaceutical Ingredient (API) that meets predetermined specifications and quality attributes.

This validation will be performed prospectively using **three consecutive commercial-scale batches** manufactured according to the approved Master Batch Record.

**Regulatory Basis:**
- ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
- ICH Q11: Development and Manufacture of Drug Substances
- EU GMP Annex 15: Qualification and Validation
- ICH Q9: Quality Risk Management

---

## 2. SCOPE

### 2.1 INCLUDED IN SCOPE

**This protocol covers:**
- Complete manufacturing process from raw materials to final packaged API
- All critical process parameters (CPPs)
- All in-process controls (IPCs)
- Final product testing per specification
- Statistical evaluation of process consistency

**Manufacturing Steps:**
1. Reaction (Synthesis)
2. Workup (Neutralization and Extraction)
3. Purification (Crystallization)
4. Drying
5. Milling
6. Packaging

### 2.2 EXCLUDED FROM SCOPE

- Equipment qualification (covered separately: IQ/OQ/PQ protocols)
- Analytical method validation (covered separately: AMV-HPLC-001, AMV-GC-001)
- Cleaning validation (covered separately: CVP-REACTOR-001)
- Raw material qualification

**Prerequisite:** All equipment used in this process must be successfully qualified (IQ/OQ/PQ completed) before process validation begins.

---

## 3. RESPONSIBILITIES

### 3.1 VALIDATION MANAGER
- Prepare and finalize this protocol
- Coordinate validation activities
- Compile and analyze validation data
- Prepare Process Validation Report (PVR-FAM-001)

### 3.2 PRODUCTION MANAGER
- Ensure manufacturing personnel are trained on the Master Batch Record
- Execute validation batches according to protocol
- Document all process parameters and deviations
- Ensure equipment is available and qualified

### 3.3 QC MANAGER
- Perform all analytical testing per protocol
- Ensure analytical methods are validated
- Review and approve all test results
- Report Out-of-Specification (OOS) results immediately

### 3.4 QA MANAGER
- Review and approve this protocol before execution
- Review batch records and test results for each validation batch
- Approve/reject batches based on acceptance criteria
- Review and approve final Process Validation Report

### 3.5 MANAGEMENT REPRESENTATIVE
- Final approval of protocol and validation report
- Ensure resources are available

---

## 4. PRODUCT DESCRIPTION

### 4.1 PRODUCT INFORMATION

**Product Name:** Fampridin (INN)  
**Chemical Name:** 4-Aminopyridine  
**Molecular Formula:** C₅H₆N₂  
**Molecular Weight:** 94.11 g/mol  
**CAS Number:** 504-24-5  

**Chemical Structure:**
```
        NH₂
         |
    N — C — C
    |       |
    C — C — C
        |
        H
```
(Pyridine ring with amino group at position 4)

**Appearance:** White to off-white crystalline powder  
**Solubility:** Freely soluble in water, soluble in ethanol  
**Therapeutic Use:** Treatment of walking impairment in multiple sclerosis patients  

### 4.2 QUALITY STANDARD

**Compendial Status:** DAC (Deutscher Arzneimittel-Codex)  
**GMP Classification:** Active Pharmaceutical Ingredient (API)  
**Target Market:** EU, Japan (PMDA approval planned)

---

## 5. MANUFACTURING PROCESS DESCRIPTION

### 5.1 PROCESS OVERVIEW

**Synthesis Route:** (Simplified for validation purposes)

The manufacturing process consists of six main steps:

**Step 1: Reaction (Synthesis)**
- Pyridine derivative reacted with appropriate reagents
- Controlled temperature and pH
- Monitored by in-process HPLC

**Step 2: Workup (Neutralization and Extraction)**
- Reaction mixture neutralized to target pH
- Extraction with organic solvent
- Aqueous/organic phase separation

**Step 3: Purification (Crystallization)**
- Solvent evaporation/concentration
- Crystallization from appropriate solvent system
- Filtration and washing

**Step 4: Drying**
- Vacuum drying at controlled temperature
- Endpoint determined by Loss on Drying (LOD)

**Step 5: Milling**
- Particle size reduction to target distribution
- Sieving (if applicable)

**Step 6: Packaging**
- Transfer to polyethylene-lined drums
- Labeling with batch number, manufacturing date, specifications

---

### 5.2 DETAILED PROCESS DESCRIPTION

#### STEP 1: REACTION (SYNTHESIS)

**Equipment:** Reactor R-101 (500 L capacity)

**Procedure:**
1. Charge starting materials to reactor:
   - Starting Material A: [XX] kg
   - Starting Material B: [XX] kg
   - Solvent: [XX] L
2. Heat to reaction temperature: **80 ± 2°C** (CPP-1)
3. Maintain reaction for: **4.0 ± 0.5 hours** (CPP-2)
4. Monitor pH: Target pH **7.0 ± 0.5** during reaction (CPP-3)
5. In-Process Control: HPLC purity ≥95% (IPC-1)

**Critical Process Parameters (CPPs):**
- **CPP-1:** Reaction temperature: 80 ± 2°C
- **CPP-2:** Reaction time: 4.0 ± 0.5 hours
- **CPP-3:** pH during reaction: 7.0 ± 0.5

**In-Process Controls:**
- **IPC-1:** Purity by HPLC ≥95%

---

#### STEP 2: WORKUP (NEUTRALIZATION AND EXTRACTION)

**Equipment:** Reactor R-102 (300 L capacity), Separator

**Procedure:**
1. Transfer reaction mixture to workup reactor R-102
2. Cool to **25 ± 5°C**
3. Adjust pH to **6.5-7.5** using [Acid/Base] (CPP-4)
4. Add extraction solvent: [XX] L
5. Mix for 30 minutes, allow phase separation
6. Separate aqueous and organic layers
7. In-Process Control: pH verification (IPC-2)

**Critical Process Parameters:**
- **CPP-4:** pH after neutralization: 6.5-7.5

**In-Process Controls:**
- **IPC-2:** pH verification: 6.5-7.5

---

#### STEP 3: PURIFICATION (CRYSTALLIZATION)

**Equipment:** Crystallizer C-101, Filter F-101

**Procedure:**
1. Concentrate organic phase by distillation under vacuum
2. Cool to **10 ± 5°C** to induce crystallization (CPP-5)
3. Hold at crystallization temperature for **2 ± 0.5 hours** (CPP-6)
4. Filter crystals on Nutsche filter F-101
5. Wash crystals with cold solvent: [XX] L
6. In-Process Control: Purity by HPLC ≥98% (IPC-3)

**Critical Process Parameters:**
- **CPP-5:** Crystallization temperature: 10 ± 5°C
- **CPP-6:** Crystallization hold time: 2 ± 0.5 hours

**In-Process Controls:**
- **IPC-3:** Purity by HPLC ≥98%

---

#### STEP 4: DRYING

**Equipment:** Vacuum Dryer VD-101

**Procedure:**
1. Transfer wet cake to vacuum dryer
2. Dry at **60 ± 5°C** under vacuum **<50 mbar** (CPP-7, CPP-8)
3. Dry until Loss on Drying (LOD) **≤0.50%** (IPC-4)
4. Typical drying time: 8-12 hours
5. Cool to room temperature under nitrogen

**Critical Process Parameters:**
- **CPP-7:** Drying temperature: 60 ± 5°C
- **CPP-8:** Vacuum level: <50 mbar

**In-Process Controls:**
- **IPC-4:** Loss on Drying (LOD) ≤0.50%

---

#### STEP 5: MILLING

**Equipment:** Mill M-101

**Procedure:**
1. Mill dried API to achieve target particle size
2. Target particle size distribution: **D50: 20-80 μm** (CPP-9)
3. In-Process Control: Particle size distribution (IPC-5)

**Critical Process Parameters:**
- **CPP-9:** Target D50: 20-80 μm

**In-Process Controls:**
- **IPC-5:** Particle size distribution D50: 20-80 μm

---

#### STEP 6: PACKAGING

**Equipment:** Packaging area

**Procedure:**
1. Transfer milled API to polyethylene-lined drums (25 kg per drum)
2. Close drums with secure lids
3. Label drums with:
   - Product name: Fampridin
   - Batch number
   - Manufacturing date
   - Quantity
   - Storage conditions: "Store at 15-25°C, protect from light"
4. Quarantine until QC release

---

### 5.3 PROCESS FLOW DIAGRAM

```
Raw Materials
     ↓
[REACTION] ← Reactor R-101 (80°C, 4h, pH 7.0)
     ↓
[WORKUP] ← Reactor R-102 (pH 6.5-7.5, Extraction)
     ↓
[CRYSTALLIZATION] ← Crystallizer C-101 (10°C, 2h)
     ↓
[FILTRATION] ← Filter F-101
     ↓
[DRYING] ← Vacuum Dryer VD-101 (60°C, <50 mbar)
     ↓
[MILLING] ← Mill M-101 (D50: 20-80 μm)
     ↓
[PACKAGING] ← Drums (25 kg)
     ↓
Quarantine → QC Testing → QA Release → Approved Stock
```

---

## 6. CRITICAL QUALITY ATTRIBUTES (CQAs)

**Critical Quality Attributes (CQAs)** are physical, chemical, biological, or microbiological properties that should be within an appropriate limit, range, or distribution to ensure the desired product quality.

### 6.1 IDENTIFIED CQAs FOR FAMPRIDIN

| CQA | Specification | Criticality | Control Method |
|-----|---------------|-------------|----------------|
| **Identity** | IR spectrum conforms to reference | High | IR Spectroscopy |
| **Assay (Purity)** | 99.0 - 101.0% | High | HPLC |
| **Impurities** | Any single impurity ≤0.10%<br>Total impurities ≤0.50% | High | HPLC |
| **Residual Solvents** | Ethanol ≤5000 ppm<br>Others per ICH Q3C | High | GC |
| **Water Content** | ≤0.50% | Medium | Karl Fischer |
| **Particle Size** | D50: 20-80 μm | Medium | Laser Diffraction |
| **Appearance** | White to off-white crystalline powder | Low | Visual |
| **Microbial Limits** | Total aerobic count ≤1000 CFU/g<br>Yeast/Mold ≤100 CFU/g<br>E. coli, Salmonella: Absent | Medium | Ph. Eur. 2.6.12 |

**Justification:**
- **Identity, Assay, Impurities:** Directly impact efficacy and safety (High criticality)
- **Residual Solvents:** Toxicological concern (High criticality)
- **Water Content, Particle Size, Microbial Limits:** Impact stability, bioavailability, and quality (Medium criticality)
- **Appearance:** Quality indicator, low impact on safety/efficacy (Low criticality)

---

## 7. CRITICAL PROCESS PARAMETERS (CPPs)

**Critical Process Parameters (CPPs)** are process parameters whose variability has an impact on a CQA and therefore should be monitored or controlled to ensure the process produces the desired quality.

### 7.1 IDENTIFIED CPPs

| CPP ID | Process Step | Parameter | Target/Range | Linked CQA | Monitoring Method |
|--------|--------------|-----------|--------------|------------|-------------------|
| **CPP-1** | Reaction | Temperature | 80 ± 2°C | Assay, Impurities | Temperature probe (continuous) |
| **CPP-2** | Reaction | Time | 4.0 ± 0.5 hours | Assay, Impurities | Timer |
| **CPP-3** | Reaction | pH | 7.0 ± 0.5 | Assay, Impurities | pH probe (continuous) |
| **CPP-4** | Workup | pH | 6.5 - 7.5 | Impurities | pH meter |
| **CPP-5** | Crystallization | Temperature | 10 ± 5°C | Particle Size, Purity | Temperature probe |
| **CPP-6** | Crystallization | Hold Time | 2 ± 0.5 hours | Particle Size, Purity | Timer |
| **CPP-7** | Drying | Temperature | 60 ± 5°C | Water Content, Residual Solvents | Temperature probe |
| **CPP-8** | Drying | Vacuum Level | <50 mbar | Water Content, Residual Solvents | Vacuum gauge |
| **CPP-9** | Milling | Particle Size (D50) | 20-80 μm | Particle Size, Dissolution | Laser Diffraction |

**Risk Assessment (ICH Q9):**
All CPPs identified through FMEA (Failure Mode and Effects Analysis) during process development. Each CPP has potential HIGH impact on product quality if out of specification.

---

## 8. IN-PROCESS CONTROLS (IPCs)

**In-Process Controls (IPCs)** are checks performed during production to monitor and, if necessary, adjust the process to ensure the final product meets specifications.

### 8.1 IDENTIFIED IPCs

| IPC ID | Process Step | Test | Acceptance Criteria | Frequency | Action if OOS |
|--------|--------------|------|---------------------|-----------|---------------|
| **IPC-1** | Reaction | Purity by HPLC | ≥95% | End of reaction (each batch) | Extend reaction time, investigate |
| **IPC-2** | Workup | pH | 6.5 - 7.5 | After neutralization | Adjust with acid/base |
| **IPC-3** | Crystallization | Purity by HPLC | ≥98% | After crystallization | Recrystallize if <98% |
| **IPC-4** | Drying | Loss on Drying (LOD) | ≤0.50% | After drying | Continue drying if >0.50% |
| **IPC-5** | Milling | Particle Size (D50) | 20-80 μm | After milling | Re-mill if out of range |

---

## 9. EQUIPMENT AND UTILITIES

### 9.1 EQUIPMENT USED

**All equipment must be qualified (IQ/OQ/PQ completed) before use in validation batches.**

| Equipment ID | Description | Qualification Status | Protocol Reference |
|--------------|-------------|----------------------|--------------------|
| R-101 | Reactor (500 L) | Qualified | IQ/OQ/PQ-REACTOR-001 |
| R-102 | Workup Reactor (300 L) | Qualified | IQ/OQ/PQ-REACTOR-002 |
| C-101 | Crystallizer | Qualified | IQ/OQ-CRYST-001 |
| F-101 | Nutsche Filter | Qualified | IQ/OQ-FILTER-001 |
| VD-101 | Vacuum Dryer | Qualified | IQ/OQ/PQ-DRYER-001 |
| M-101 | Mill | Qualified | IQ/OQ-MILL-001 |

### 9.2 UTILITIES

| Utility | Specification | Qualification Status |
|---------|---------------|----------------------|
| **Purified Water** | Ph. Eur., Conductivity ≤1.3 µS/cm | Qualified (IQ/OQ/PQ-WATER-001) |
| **HVAC** | Production area ISO 8, Pressure +15 Pa | Qualified (IQ/OQ/PQ-HVAC-001) |
| **Compressed Air** | Oil-free, dry | Qualified (IQ/OQ-CA-001) |
| **Nitrogen** | Inert gas for drying | Qualified |

---

## 10. SAMPLING PLAN

### 10.1 RAW MATERIAL SAMPLING

**All raw materials must be released by QA before use.**

- Identity testing: 100% of containers
- Full testing per specification: Per approved sampling plan (e.g., skip-lot testing if justified)

### 10.2 IN-PROCESS SAMPLING

| Sample ID | Process Step | Sample Point | Test | Frequency |
|-----------|--------------|--------------|------|-----------|
| **IPS-1** | Reaction | End of reaction | HPLC purity | Each batch |
| **IPS-2** | Workup | After neutralization | pH | Each batch |
| **IPS-3** | Crystallization | After crystallization | HPLC purity | Each batch |
| **IPS-4** | Drying | After drying | LOD | Each batch |
| **IPS-5** | Milling | After milling | Particle size | Each batch |

**Sample Size:** Minimum 10 g per sample (or as required by analytical method)

**Sample Handling:**
- Label immediately with batch number, sample ID, date, sampler initials
- Store under appropriate conditions (room temperature, protected from light)
- Submit to QC within 2 hours of sampling

### 10.3 FINAL PRODUCT SAMPLING

**Sampling per approved SOP:**
- Sample from multiple drums (minimum 3 drums or 10% of drums, whichever is greater)
- Composite sample for homogeneity
- Minimum sample size: 100 g

---

## 11. ANALYTICAL TESTING PLAN

### 11.1 IN-PROCESS TESTING

| Test | Method | Specification | Validated? |
|------|--------|---------------|------------|
| HPLC Purity (IPC-1, IPC-3) | HPLC-IPC-001 | IPC-1: ≥95%<br>IPC-3: ≥98% | Yes (AMV-HPLC-001) |
| pH (IPC-2) | pH Meter | 6.5 - 7.5 | Yes (SOP-pH-001) |
| Loss on Drying (IPC-4) | Ph. Eur. 2.2.32 | ≤0.50% | Yes |
| Particle Size (IPC-5) | Laser Diffraction | D50: 20-80 μm | Yes (AMV-PSD-001) |

### 11.2 FINAL PRODUCT TESTING

**Full specification testing per API Specification (SPEC-FAM-001):**

| Test | Method | Acceptance Criteria | Validated? |
|------|--------|---------------------|------------|
| **Appearance** | Visual | White to off-white crystalline powder | N/A |
| **Identity (IR)** | IR Spectroscopy | Conforms to reference | Yes |
| **Identity (HPLC RT)** | HPLC | Matches reference ±2% | Yes (AMV-HPLC-001) |
| **Assay** | HPLC | 99.0 - 101.0% | Yes (AMV-HPLC-001) |
| **Impurities** | HPLC | Any single ≤0.10%<br>Total ≤0.50% | Yes (AMV-HPLC-001) |
| **Water Content** | Karl Fischer | ≤0.50% | Yes (AMV-KF-001) |
| **Residual Solvents** | GC | Ethanol ≤5000 ppm<br>Others per ICH Q3C | Yes (AMV-GC-001) |
| **Particle Size** | Laser Diffraction | D50: 20-80 μm | Yes (AMV-PSD-001) |
| **Microbial Limits** | Ph. Eur. 2.6.12 | Total aerobic ≤1000 CFU/g<br>Yeast/Mold ≤100 CFU/g<br>E. coli, Salmonella: Absent | Yes |

**All analytical methods must be validated per ICH Q2(R1) before use.**

---

## 12. ACCEPTANCE CRITERIA

### 12.1 BATCH ACCEPTANCE CRITERIA

**Each validation batch is acceptable if:**

**1. Process Compliance:**
- All CPPs maintained within validated ranges (see Section 7)
- All IPCs meet acceptance criteria (see Section 8)
- No critical deviations (or deviations are investigated and justified)

**2. Final Product Compliance:**
- All final product tests meet specification (see Section 11.2)

**3. Yield:**
- Yield within expected range: **85-95%** (theoretical yield calculated from starting materials)
- Significant yield deviations (e.g., <80%) require investigation

### 12.2 OVERALL VALIDATION ACCEPTANCE CRITERIA

**Process Validation is successful if:**

**1. All Three Batches Pass:**
- All 3 validation batches meet individual batch acceptance criteria

**2. Statistical Consistency:**
- Mean, standard deviation, and range for CQAs are acceptable (see Section 15)
- No significant trends indicating process drift

**3. No Critical Deviations:**
- No unresolved critical deviations
- All deviations investigated with CAPA (if needed)

**4. Documentation Complete:**
- All batch records complete and signed
- All test results documented and approved by QC/QA

---

## 13. VALIDATION BATCH EXECUTION

### 13.1 VALIDATION BATCHES

**Three consecutive commercial-scale batches will be manufactured:**

| Batch Number | Planned Manufacturing Date | Batch Size | Status |
|--------------|---------------------------|------------|--------|
| [To be assigned] | [Month 7, 2026] | 100 kg | Planned |
| [To be assigned] | [Month 8, 2026] | 100 kg | Planned |
| [To be assigned] | [Month 9, 2026] | 100 kg | Planned |

**Batch Size Justification:**
- 100 kg represents the intended commercial batch size
- Equipment operated at normal capacity (R-101: 500 L, 20% fill)

### 13.2 PERSONNEL

**All personnel involved in validation batches must be:**
- Trained on Master Batch Record (MBR-FAM-001)
- Trained on GMP and validation requirements
- Competency assessed and documented

### 13.3 MANUFACTURING SEQUENCE

**Batches will be manufactured consecutively with minimal time between batches:**
- No process or equipment changes between batches
- Same raw material lots used (where possible)
- Same personnel (where possible)

### 13.4 BATCH RECORD EXECUTION

**Each batch will be manufactured according to:**
- Master Batch Record (MBR-FAM-001)
- This Process Validation Protocol (PVP-FAM-001)

**All process parameters, IPCs, and deviations must be documented in the batch record.**

---

## 14. DATA RECORDING AND DOCUMENTATION

### 14.1 BATCH MANUFACTURING RECORD

**For each validation batch, the following data will be recorded:**

**Raw Materials:**
- Name, batch number, quantity used, supplier

**Process Parameters:**
- All CPPs (temperature, time, pH, vacuum, etc.)
- Recorded continuously or at defined intervals

**In-Process Controls:**
- All IPC results (HPLC purity, pH, LOD, particle size)

**Yield:**
- Theoretical yield
- Actual yield
- % Yield

**Deviations:**
- Description, impact assessment, corrective action

**Signatures:**
- Operator, Production Supervisor, QA Reviewer

### 14.2 DATA RECORDING TABLES

**The following data tables are included in Appendix A (to be completed during execution):**

- **Table A1:** Raw Material Usage (per batch)
- **Table A2:** Critical Process Parameters (CPP) – Batch 1
- **Table A3:** Critical Process Parameters (CPP) – Batch 2
- **Table A4:** Critical Process Parameters (CPP) – Batch 3
- **Table A5:** In-Process Controls (IPC) – All Batches
- **Table A6:** Final Product Test Results – All Batches
- **Table A7:** Yield Summary – All Batches

---

## 15. STATISTICAL EVALUATION

### 15.1 OBJECTIVE

Statistical evaluation will be performed to demonstrate:
- Process consistency across 3 batches
- CQAs are within acceptable limits
- No adverse trends

### 15.2 PARAMETERS TO BE EVALUATED

**For each CQA, calculate:**
- **Mean (Average)**
- **Standard Deviation (SD)**
- **Relative Standard Deviation (RSD%)**
- **Range (Min - Max)**

**Evaluated CQAs:**
- Assay (%)
- Total Impurities (%)
- Water Content (%)
- Particle Size D50 (μm)
- Yield (%)

### 15.3 STATISTICAL ACCEPTANCE CRITERIA

**General Criteria:**
- **RSD ≤5%** for Assay, Impurities, Water Content
- **RSD ≤15%** for Particle Size (acceptable variability)
- No significant trend (e.g., increasing impurities, decreasing yield)

**Example Statistical Table (to be completed in validation report):**

| CQA | Batch 1 | Batch 2 | Batch 3 | Mean | SD | RSD (%) | Acceptance |
|-----|---------|---------|---------|------|----|---------| -----------|
| Assay (%) | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | RSD ≤5% |
| Total Impurities (%) | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | RSD ≤5% |
| Water Content (%) | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | RSD ≤5% |
| Particle Size D50 (μm) | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | RSD ≤15% |
| Yield (%) | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | [TBD] | Range 85-95% |

**TBD = To Be Determined (filled in after batch execution)**

### 15.4 TREND ANALYSIS

**Visual inspection of data:**
- Plot Assay, Impurities, Yield across 3 batches
- Check for increasing or decreasing trends
- Trends may indicate process drift (requires investigation)

---

## 16. DEVIATIONS

### 16.1 DEVIATION MANAGEMENT

**Any deviation from this protocol or the Master Batch Record must be:**
- Documented immediately in the batch record
- Reported to QA within 24 hours
- Investigated for root cause
- Impact on product quality assessed

### 16.2 DEVIATION CLASSIFICATION

**Critical Deviation:**
- Direct impact on product quality or patient safety
- Examples: CPP out of range, equipment failure, OOS result
- Requires immediate action and CAPA

**Major Deviation:**
- Potential impact on quality, but batch may still be acceptable
- Requires investigation and justification

**Minor Deviation:**
- No impact on quality (e.g., documentation error, late sampling)
- Documented, but limited investigation

### 16.3 IMPACT ON VALIDATION

**Critical Deviations:**
- Batch may be rejected
- Validation may need to be repeated (if multiple batches affected)

**Major Deviations:**
- Acceptable if investigation shows no impact on quality
- May require additional testing

**Minor Deviations:**
- Generally do not impact validation outcome

---

## 17. CONCLUSION AND APPROVAL

### 17.1 COMPLETION OF VALIDATION

**After all 3 validation batches are manufactured and tested:**

1. Validation Manager compiles all data
2. Statistical evaluation performed (Section 15)
3. All deviations reviewed and resolved
4. Process Validation Report (PVR-FAM-001) prepared

### 17.2 VALIDATION REPORT

**The Process Validation Report will include:**
- Summary of results (all batches)
- Statistical analysis
- Deviations and investigations
- Conclusion: **Process is validated** or **Additional batches required**
- Recommendations (if any)

### 17.3 APPROVAL

**The validation is successful when:**
- All acceptance criteria met (Sections 12.1 and 12.2)
- Process Validation Report approved by:
  - Validation Manager
  - QA Manager
  - Production Manager
  - Management Representative

**After approval:**
- Routine commercial production may begin
- Process must be maintained in validated state (per Change Control SOP)

---

## 18. APPENDICES

### APPENDIX A: DATA RECORDING TABLES

**(To be completed during validation batch execution)**

#### TABLE A1: RAW MATERIAL USAGE

| Raw Material | Specification | Batch 1<br>Lot No. / Qty | Batch 2<br>Lot No. / Qty | Batch 3<br>Lot No. / Qty |
|--------------|---------------|-------------------------|-------------------------|-------------------------|
| Starting Material A | [Spec] | | | |
| Starting Material B | [Spec] | | | |
| Solvent (Ethanol) | [Spec] | | | |
| [Other materials] | | | | |

---

#### TABLE A2: CRITICAL PROCESS PARAMETERS – BATCH 1

| CPP ID | Parameter | Target/Range | Actual Value | Within Spec? (Y/N) | Comments |
|--------|-----------|--------------|--------------|---------------------|----------|
| CPP-1 | Reaction Temp (°C) | 80 ± 2 | | | |
| CPP-2 | Reaction Time (h) | 4.0 ± 0.5 | | | |
| CPP-3 | Reaction pH | 7.0 ± 0.5 | | | |
| CPP-4 | Workup pH | 6.5 - 7.5 | | | |
| CPP-5 | Crystallization Temp (°C) | 10 ± 5 | | | |
| CPP-6 | Crystallization Time (h) | 2 ± 0.5 | | | |
| CPP-7 | Drying Temp (°C) | 60 ± 5 | | | |
| CPP-8 | Vacuum (mbar) | <50 | | | |
| CPP-9 | Particle Size D50 (μm) | 20-80 | | | |

**(Repeat Table A2 structure for Batch 2 and Batch 3)**

---

#### TABLE A5: IN-PROCESS CONTROLS – ALL BATCHES

| IPC ID | Test | Acceptance Criteria | Batch 1 | Batch 2 | Batch 3 | Pass/Fail |
|--------|------|---------------------|---------|---------|---------|-----------|
| IPC-1 | HPLC Purity (Reaction) | ≥95% | | | | |
| IPC-2 | pH (Workup) | 6.5-7.5 | | | | |
| IPC-3 | HPLC Purity (Crystallization) | ≥98% | | | | |
| IPC-4 | LOD (Drying) | ≤0.50% | | | | |
| IPC-5 | Particle Size D50 (Milling) | 20-80 μm | | | | |

---

#### TABLE A6: FINAL PRODUCT TEST RESULTS – ALL BATCHES

| Test | Specification | Batch 1 | Batch 2 | Batch 3 | Pass/Fail |
|------|---------------|---------|---------|---------|-----------|
| Appearance | White to off-white powder | | | | |
| Identity (IR) | Conforms | | | | |
| Identity (HPLC RT) | Matches reference | | | | |
| Assay (%) | 99.0-101.0 | | | | |
| Total Impurities (%) | ≤0.50 | | | | |
| Largest Impurity (%) | ≤0.10 | | | | |
| Water Content (%) | ≤0.50 | | | | |
| Residual Ethanol (ppm) | ≤5000 | | | | |
| Particle Size D50 (μm) | 20-80 | | | | |
| Microbial Count (CFU/g) | ≤1000 | | | | |
| Yeast/Mold (CFU/g) | ≤100 | | | | |
| E. coli | Absent | | | | |
| Salmonella | Absent | | | | |

---

#### TABLE A7: YIELD SUMMARY

| Batch | Theoretical Yield (kg) | Actual Yield (kg) | % Yield | Within Range (85-95%)? | Comments |
|-------|------------------------|-------------------|---------|------------------------|----------|
| Batch 1 | [TBD] | | | | |
| Batch 2 | [TBD] | | | | |
| Batch 3 | [TBD] | | | | |
| **Average** | | | | | |

---

### APPENDIX B: ABBREVIATIONS

- API: Active Pharmaceutical Ingredient
- CAPA: Corrective and Preventive Action
- CFU: Colony Forming Units
- CPP: Critical Process Parameter
- CQA: Critical Quality Attribute
- DAC: Deutscher Arzneimittel-Codex
- FMEA: Failure Mode and Effects Analysis
- GC: Gas Chromatography
- GMP: Good Manufacturing Practice
- HPLC: High-Performance Liquid Chromatography
- ICH: International Council for Harmonisation
- IPC: In-Process Control
- IQ: Installation Qualification
- IR: Infrared Spectroscopy
- LOD: Loss on Drying
- OOS: Out-of-Specification
- OQ: Operational Qualification
- Ph. Eur.: European Pharmacopoeia
- PMDA: Pharmaceuticals and Medical Devices Agency (Japan)
- PQ: Performance Qualification
- PVP: Process Validation Protocol
- PVR: Process Validation Report
- QA: Quality Assurance
- QC: Quality Control
- RSD: Relative Standard Deviation
- RT: Retention Time
- SD: Standard Deviation
- SOP: Standard Operating Procedure
- URS: User Requirement Specification

---

## 19. REFERENCES

**Regulatory Guidelines:**
- ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
- ICH Q11: Development and Manufacture of Drug Substances
- ICH Q9: Quality Risk Management
- ICH Q2(R1): Validation of Analytical Procedures
- ICH Q3C: Impurities: Guideline for Residual Solvents
- EU GMP Annex 15: Qualification and Validation
- Ph. Eur. (European Pharmacopoeia)

**Internal Documents:**
- QM-001: Quality Manual
- MVP-001: Master Validation Plan
- MBR-FAM-001: Master Batch Record – Fampridin
- SPEC-FAM-001: Specification – Fampridin API
- AMV-HPLC-001: Analytical Method Validation – HPLC (Assay, Impurities)
- AMV-GC-001: Analytical Method Validation – GC (Residual Solvents)
- AMV-KF-001: Analytical Method Validation – Karl Fischer (Water Content)
- IQ/OQ/PQ Protocols for all equipment (Reactors, Dryer, Mill, etc.)

---

## REVISION HISTORY

| Version | Date | Author | Description of Changes | Approved By |
|---------|------|--------|------------------------|-------------|
| 1.0 | 04.12.2025 | Validation Department | Initial Protocol | [Pending Approval] |

---

## APPROVAL SIGNATURES

**Prepared by:**  
[Name, Title: Validation Manager]  
Signature: ________________  
Date: __________

**Reviewed by:**  
[Name, Title: QA Manager]  
Signature: ________________  
Date: __________

**Reviewed by:**  
[Name, Title: Production Manager]  
Signature: ________________  
Date: __________

**Reviewed by:**  
[Name, Title: QC Manager]  
Signature: ________________  
Date: __________

**Approved by:**  
[Name, Title: Management Representative]  
Signature: ________________  
Date: __________

---

**END OF PROCESS VALIDATION PROTOCOL**

**Protocol Status:** Draft – Pending Approval  
**Effective Date:** Upon approval and signature  
**Supersedes:** N/A (New document)
